Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BFAR | CTRPv2 | pan-cancer | AAC | -0.14 | 5e-05 |
mRNA | RPL26L1 | CTRPv2 | pan-cancer | AAC | -0.14 | 5e-05 |
mRNA | INSR | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | C9orf72 | CTRPv2 | pan-cancer | AAC | 0.13 | 5e-05 |
mRNA | AATK-AS1 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | ZNF709 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
mRNA | ZNF775 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
mRNA | UEVLD | CTRPv2 | pan-cancer | AAC | -0.16 | 6e-05 |
mRNA | MEGF11 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | TAPT1 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |